As 23andMe Crumbles, It Ceases All Efforts to Develop Drugs Using DNA Data

Image by Getty ImagesIn the year since its devastating hack, 23andMe has lost virtually all its stock value and most of its governing board — and somehow, things just keep getting worse for the one-time DNA kit wunderkind.As CEO Anne Wojcicki announced in a press release, 23andMe is not only laying off 40 percent of its remaining workforce — about 200 employees total — but also completely kiboshing its therapeutics program that was seeking to use AI and the company’s hoard of genetic information to develop new drugs.”We are taking…

This content is for Member members only.
Log In Register